The findings on tumor mutational burden (TMB) may fill a gap in biomarkers for patients who have non–small cell lung cancer (NSCLC). The findings could make it easier for clinicians to personalize ...

A recent study found that patients with advanced solid cancers with high tumor mutational burden (TMB) saw improved outcomes on immune checkpoint inhibitors (ICIs) compared with patients who had ...

In contrast to what has been seen in other types of cancer, in which high tumor mutational burden (TMB) predicts response to immunotherapy, the situation appears to be reversed in cases of recurrent ...

JCO Precision Oncology Conversations features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations as they ...